Screening and diagnosis are different workflows
Asymptomatic screening can add early-warning information; symptoms require direct medical evaluation.
Partner audience · Family doctors
The value of an early signal depends on the clinician who can place it in context.
Patients are asking for broader preventive options. miRoncol’s role is to provide a scientifically grounded molecular layer; the physician’s role is to connect that information to history, screening, symptoms and the appropriate next step.
miCheckup is screening information, not diagnosis. A suspected signal requires established clinical evaluation; a result without a signal does not rule out cancer.
Patient needBroader proactive screening questions
Physician valueContext, judgment and continuity
Test roleAdditional early-warning information
BoundaryNot diagnosis or replacement screening
Why the physician remains central
A laboratory result can identify a pattern. It cannot manage the person.
The test becomes clinically useful only when the result is interpreted against the patient’s complete context and linked to a responsible follow-up pathway.
Both result categories have limits
A negative result cannot eliminate risk, while a suspected signal cannot establish that cancer is present.
The physician connects today with what comes next
Clinical knowledge is essential for recommended screening, imaging, referral and communication.
How it fits into medical practice
Use the test as an added information layer within established care.
A clear workflow reduces confusion for the patient and avoids asking primary care to absorb an undefined result.
Confirm the intended-use population
Review eligibility, exclusions and whether symptoms require a different pathway.
Preserve standard screening
Continue mammography, colorectal screening, Pap/HPV testing and other recommended programs.
Use physician-reviewed reporting
Explain what the result means, what it does not mean and what follow-up is appropriate.
Close the loop
Ensure imaging and specialist referral are coordinated when further investigation is indicated.
What this partnership creates
A trusted adoption pathway,and the clinical feedback needed to improve responsibly.
Physician participation does more than support distribution. It improves patient selection, communication, follow-up and the quality of future evidence.
An early signal with a guide
The patient receives context and a defined next step rather than navigating uncertainty alone.
A structured answer to patient demand
Clinicians can discuss a published, bounded option instead of leaving patients to evaluate direct-to-consumer claims alone.
Clinically meaningful feedback
With consent and formal study governance, real-world pathways can help evaluate performance, follow-up and utility.
Responsible clinical adoption
New information should strengthen care,not create a parallel unmanaged pathway.
Clinical materials, responsibilities and escalation criteria should be agreed before implementation.
Practice requirements
Clarity before launch
- Define who is eligible and who is not.
- Train clinicians on published evidence and limitations.
- Specify how each result is communicated.
- Establish imaging, referral and documentation pathways.
Clinical boundaries
What the result cannot replace
- Symptom assessment.
- Recommended population screening.
- Diagnostic imaging, pathology or biopsy.
- Individual medical judgment.
Bring the signal into clinical context
Give proactive patients information without leaving them alone with it.
Start a conversation about eligibility, physician review and the follow-up pathway your practice can support.